|
Faron Pharmaceuticals Ltd - Turku, Finland-based developer of cancer immunotherapies - Appoints Ralph Hughes as chief business officer, effective from next Wednesday. Notes Hughes’ prior experience as senior vice president at PharmaVentures, and his extensive experience in commercial due diligence, market access and the business development process. Adds that he will be part of the management team and the business development team. ‘We are delighted to have such an experienced pharmaceutical market access and strategic commercial development expert to join us as the new CBO’, says Chief Executive Juho Jalkanen. ‘Ralph’s proven track record in biopharma leadership and his experience align perfectly with our corporate development efforts and strategic growth initiatives.’ Current stock price: 227.00 pence, up 2.7% on Wednesday afternoon in London 12-month change: up 15% Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
